Phoenix Asia Holdings Ltd (PHOE) SEC Filings & Earnings Calls
EquiReason read 4 Phoenix Asia Holdings Ltd SEC filings in the last 12 months. Latest: 20-F on 2026-08-14 — Annual results show revenue decline, gross margin collapse from 29.5% to 4.6%, and a net loss of $1.2M..
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 324.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Mar, in 156 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
14 Aug 202620-FAnnual results show revenue decline, gross margin collapse from 29.5% to 4.6%, and a net loss of $1.2M.earningsopen
Figures in the filing · each found in the filing text
| Gross profit margin · FY2026 | 4.6% | |
| Backlog · FY2026 | $7M | +609% y/y |
| Number of employees · FY2026 | 32 |
Risks flagged
Customer concentration risk
“The total revenue attributable to our five largest customers in aggregate accounted for approximately 97.0% of the total revenue for the fiscal year ended March 31, 2026.” · word for word
Project non-recurrence risk
“Our revenue is typically derived from projects which are non-recurrent in nature and our customers are under no obligation to award projects to us.” · word for word
Cost overrun risk
“We typically bear the risk of delays and cost overruns in our projects and we are generally unable to pass these costs to our customers.” · word for word
Subcontractor performance risk
“We may be affected by the non-performance, inappropriate, or poor quality of works rendered by our subcontractors.” · word for word
4 May 20266-KPhoenix Asia Holdings entered into a stock acquisition agreement to acquire ACEA Pharma, a clinical-stage pharmaceutical company, for $1B in stock, with closing expected Q2 2026 subject to regulatory approvals.acquisitionopen
Risks flagged
Acquisition consideration is all stock, diluting existing shareholders; $20M convertible note adds potential further dilution.
“100,000,000 newly-issued ordinary shares...convertible promissory note...convertible into ordinary shares of the Company at a conversion price of $10.00 per share” · word for word
Closing subject to HSR antitrust review and Nasdaq approval, creating execution risk.
“subject to the satisfaction of the customary closing conditions and the receipt of all necessary regulatory approvals, including without limitation, that (i) all applicable waiting periods...under the Hart-Scott-Rodino Antitrust Improvements Act...and (ii) the receipt of any approval, clearance, confirmation, or other determination from Nasdaq” · word for word
31 Mar 20266-KPhoenix Asia Holdings reported unaudited results for H1 FY2025 (six months ended Sep 30, 2025): revenue $3.51M (down 7.3% YoY), net income $0.20M (down 68.6% YoY), EPS $0.01.earningsopen
Figures in the filing · each found in the filing text
| Revenue · H1 FY2025 | $4M | -7% y/y |
| Net income · H1 FY2025 | $198336.00 | -69% y/y |
| Earnings per share (diluted) · H1 FY2025 | $0.01 | -75% y/y |
| Total assets · Sep 30, 2025 | $9M | |
| Cash at banks · Sep 30, 2025 | $2M |
Risks flagged
Revenue and profit declining sharply; gross margin compression indicates cost pressures or pricing weakness.
“Revenue -7.3% YoY; Net income -68.6% YoY; Gross profit margin 21.1% vs 28.5%”
Cash balance declining; cash at banks down 36% from March 2025.
“Cash at banks 1,521,280 (Sep 30, 2025) vs 2,376,362 (Mar 31, 2025)”
3 Nov 20256-KPhoenix Asia Holdings appointed Ms. Yafei Xie as non-independent director and Ms. Yaqiao Xie as independent director, effective Oct 31, 2025, expanding board by two members.open
Risks flagged
No material risk changes; routine board expansion.
Phoenix Asia Holdings Ltd — questions
- What did Phoenix Asia Holdings Ltd file recently?
- 4 SEC filings in the last 12 months. Latest: 20-F on 2026-08-14 — Annual results show revenue decline, gross margin collapse from 29.5% to 4.6%, and a net loss of $1.2M.
Every figure on this page comes from Phoenix Asia Holdings Ltd's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.